Cargando…

Saleability of anti-malarials in private drug shops in Muheza, Tanzania: a baseline study in an era of assumed artemisinin combination therapy (ACT)

BACKGROUND: Artemether-lumefantrine (ALu) replaced sulphadoxine-pymimethamine (SP) as the official first-line anti-malarial in Tanzania in November 2006. So far, artemisinin combination therapy (ACT) is contra-indicated during pregnancy by the national malaria treatment guidelines, and pregnant wome...

Descripción completa

Detalles Bibliográficos
Autores principales: Ringsted, Frank M, Massawe, Isolide S, Lemnge, Martha M, Bygbjerg, Ib C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3167767/
https://www.ncbi.nlm.nih.gov/pubmed/21843328
http://dx.doi.org/10.1186/1475-2875-10-238
_version_ 1782211281074257920
author Ringsted, Frank M
Massawe, Isolide S
Lemnge, Martha M
Bygbjerg, Ib C
author_facet Ringsted, Frank M
Massawe, Isolide S
Lemnge, Martha M
Bygbjerg, Ib C
author_sort Ringsted, Frank M
collection PubMed
description BACKGROUND: Artemether-lumefantrine (ALu) replaced sulphadoxine-pymimethamine (SP) as the official first-line anti-malarial in Tanzania in November 2006. So far, artemisinin combination therapy (ACT) is contra-indicated during pregnancy by the national malaria treatment guidelines, and pregnant women depend on SP for Intermittent Preventive Treatment (IPTp) during pregnancy. SP is still being dispensed by private drug stores, but it is unknown to which extent. If significant, it may undermine its official use for IPTp through induction of resistance. The main study objective was to perform a baseline study of the private market for anti-malarials in Muheza town, an area with widespread anti-malarial drug resistance, prior to the implementation of a provider training and accreditation programme that will allow accredited drug shops to sell subsidized ALu. METHODS: All drug shops selling prescription-only anti-malarials, in Muheza town, Tanga Region voluntarily participated from July to December 2009. Qualitative in-depth interviews were conducted with owners or shopkeepers on saleability of anti-malarials, and structured questionnaires provided quantitative data on drugs sales volume. RESULTS: All surveyed drug shops illicitly sold SP and quinine (QN), and legally amodiaquine (AQ). Calculated monthly sale was 4,041 doses, in a town with a population of 15,000 people. Local brands of SP accounted for 74% of sales volume, compared to AQ (13%), QN (11%) and ACT (2%). CONCLUSIONS: In community practice, the saleability of ACT was negligible. SP was best-selling, and use was not reserved for IPTp, as stipulated in the national anti-malarial policy. It is a major reason for concern that such drug-pressure in the community equals de facto intermittent presumptive treatment. In an area where SP drug resistance remains high, unregulated SP dispensing to people other than pregnant women runs the risk of eventually jeopardizing the effectiveness of the IPTp strategy. Further studies are recommended to find out barriers for ACT utilization and preference for self-medication and to train private drug dispensers.
format Online
Article
Text
id pubmed-3167767
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31677672011-09-07 Saleability of anti-malarials in private drug shops in Muheza, Tanzania: a baseline study in an era of assumed artemisinin combination therapy (ACT) Ringsted, Frank M Massawe, Isolide S Lemnge, Martha M Bygbjerg, Ib C Malar J Research BACKGROUND: Artemether-lumefantrine (ALu) replaced sulphadoxine-pymimethamine (SP) as the official first-line anti-malarial in Tanzania in November 2006. So far, artemisinin combination therapy (ACT) is contra-indicated during pregnancy by the national malaria treatment guidelines, and pregnant women depend on SP for Intermittent Preventive Treatment (IPTp) during pregnancy. SP is still being dispensed by private drug stores, but it is unknown to which extent. If significant, it may undermine its official use for IPTp through induction of resistance. The main study objective was to perform a baseline study of the private market for anti-malarials in Muheza town, an area with widespread anti-malarial drug resistance, prior to the implementation of a provider training and accreditation programme that will allow accredited drug shops to sell subsidized ALu. METHODS: All drug shops selling prescription-only anti-malarials, in Muheza town, Tanga Region voluntarily participated from July to December 2009. Qualitative in-depth interviews were conducted with owners or shopkeepers on saleability of anti-malarials, and structured questionnaires provided quantitative data on drugs sales volume. RESULTS: All surveyed drug shops illicitly sold SP and quinine (QN), and legally amodiaquine (AQ). Calculated monthly sale was 4,041 doses, in a town with a population of 15,000 people. Local brands of SP accounted for 74% of sales volume, compared to AQ (13%), QN (11%) and ACT (2%). CONCLUSIONS: In community practice, the saleability of ACT was negligible. SP was best-selling, and use was not reserved for IPTp, as stipulated in the national anti-malarial policy. It is a major reason for concern that such drug-pressure in the community equals de facto intermittent presumptive treatment. In an area where SP drug resistance remains high, unregulated SP dispensing to people other than pregnant women runs the risk of eventually jeopardizing the effectiveness of the IPTp strategy. Further studies are recommended to find out barriers for ACT utilization and preference for self-medication and to train private drug dispensers. BioMed Central 2011-08-15 /pmc/articles/PMC3167767/ /pubmed/21843328 http://dx.doi.org/10.1186/1475-2875-10-238 Text en Copyright ©2011 Ringsted et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Ringsted, Frank M
Massawe, Isolide S
Lemnge, Martha M
Bygbjerg, Ib C
Saleability of anti-malarials in private drug shops in Muheza, Tanzania: a baseline study in an era of assumed artemisinin combination therapy (ACT)
title Saleability of anti-malarials in private drug shops in Muheza, Tanzania: a baseline study in an era of assumed artemisinin combination therapy (ACT)
title_full Saleability of anti-malarials in private drug shops in Muheza, Tanzania: a baseline study in an era of assumed artemisinin combination therapy (ACT)
title_fullStr Saleability of anti-malarials in private drug shops in Muheza, Tanzania: a baseline study in an era of assumed artemisinin combination therapy (ACT)
title_full_unstemmed Saleability of anti-malarials in private drug shops in Muheza, Tanzania: a baseline study in an era of assumed artemisinin combination therapy (ACT)
title_short Saleability of anti-malarials in private drug shops in Muheza, Tanzania: a baseline study in an era of assumed artemisinin combination therapy (ACT)
title_sort saleability of anti-malarials in private drug shops in muheza, tanzania: a baseline study in an era of assumed artemisinin combination therapy (act)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3167767/
https://www.ncbi.nlm.nih.gov/pubmed/21843328
http://dx.doi.org/10.1186/1475-2875-10-238
work_keys_str_mv AT ringstedfrankm saleabilityofantimalarialsinprivatedrugshopsinmuhezatanzaniaabaselinestudyinaneraofassumedartemisinincombinationtherapyact
AT massaweisolides saleabilityofantimalarialsinprivatedrugshopsinmuhezatanzaniaabaselinestudyinaneraofassumedartemisinincombinationtherapyact
AT lemngemartham saleabilityofantimalarialsinprivatedrugshopsinmuhezatanzaniaabaselinestudyinaneraofassumedartemisinincombinationtherapyact
AT bygbjergibc saleabilityofantimalarialsinprivatedrugshopsinmuhezatanzaniaabaselinestudyinaneraofassumedartemisinincombinationtherapyact